Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclooxygenases (COX), also known as prostaglandin-endoperoxide synthases (PTGS), are enzymes that catalyze the first committed step in prostaglandin biosynthesis. They convert arachidonic acid to prostaglandin G2 (PGG2) and then to prostaglandin H2 (PGH2), a precursor for various prostaglandins, thromboxanes, and prostacyclins. There are two main isoforms, COX-1 and COX-2, with differing expression patterns and roles in physiological and pathological processes. COX enzymes are targets for NSAIDs which inhibit prostaglandin production to reduce inflammation and pain.
Inhibition of cyclooxygenase activity, preventing the synthesis of prostaglandins.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostaglandin synthesis enzyme (cyclooxygenase).